Company Overview - Zevra Therapeutics (ZVRA) shares increased by 5.1% to close at $9.41, with trading volume significantly higher than usual [1] - The stock has shown a 0.9% gain over the past four weeks [1] Product Performance - The rise in stock price is linked to positive investor sentiment regarding the initial uptake of Miplyffa (arimoclomol), which received FDA approval for Niemann-Pick disease type C in September 2024 [2] - Miplyffa generated sales of $17.1 million in Q1 2025 [2] Earnings Expectations - Zevra Therapeutics is projected to report quarterly earnings of $0.65 per share, reflecting a year-over-year increase of 235.4% [3] - Expected revenues for the upcoming quarter are $71.83 million, representing a 1514.2% increase from the same quarter last year [3] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a potential lack of momentum in earnings estimate revisions [4] Industry Context - Zevra Therapeutics is categorized under the Zacks Medical - Drugs industry, which includes other companies like Xeris Biopharma (XERS) [5] - Xeris Biopharma's stock closed 1.5% higher at $4.73, with a slight return of 0.2% over the past month [5] - Xeris Biopharma's consensus EPS estimate has also remained unchanged, with a year-over-year change of 70% [6]

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -41.18%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.14 per share when it actually produced a loss of $0.19, delivering a surprise of -35.71%.Over the last four ...

Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.13 per share when it actually produced a loss of $0.15, delivering a surprise of -15.38%.Over the last four quarters, ...

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -54.55%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.05 per share when it actually produced a loss of $0.05, delivering no surprise.Over the last four quarters, the compa ...

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -16.67%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.14 per share when it actually produced a loss of $0.10, delivering a surprise of 28.57%.Over the last four quart ...